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Abstract 
Our objective is to estimate the extent to which clinical and non-clinical factors are 
associated with physicians’ prescribing patterns for statins.  The data are from the 
National Ambulatory Medical Care Survey for the period 1992 through 2004.  The three 
samples examined included more than 14,000 patients who were diagnosed with coronary 
heart disease, high cholesterol, or diabetes, individuals who are most likely to benefit 
from being prescribed a statin drug.  Using a multinomial logit framework, we find 
disparities in prescribing patterns based on non-clinical factors.  Namely, whites and 
patients who have private insurance are more likely to be prescribed a statin than non-
whites and those with public insurance.  Also, even though a large increase occurred in 
the uptake of statins over the period 1992 to 2004, our results for 2004 show that only 
about 50 percent of patients diagnosed with coronary heart disease were prescribed a 
statin.  Because coronary heart disease is the leading cause of death in the U.S. and 
currently is estimated to cost over $150 billion annually in the U.S. in direct and indirect 
costs, observed differences in prescribing patterns along these dimensions is troubling 
and should be part of discussions dealing with health care reform.  
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The objective of the paper is to estimate the factors that influence whether 
physicians prescribe statins and/or other lipid-lowering drugs to patients diagnosed with 
coronary heart disease (CHD), dyslipidemia, and diabetes.  In 2004, coronary heart 
disease (CHD) affected 15.8 million people in the U.S., and is the leading cause of deaths 
with over 450,000 deaths annually.  Not only is CHD the leading cause of death, but in 
2007 it is estimated to cost over $150 billion in direct and indirect costs (American Heart 
Association, 2007).
1  There are several risk factors for CHD, of which diabetes and high 
levels of cholesterol, low-density lipoprotein cholesterol (LDL), are relevant to the 
current paper.   
Given the well-documented success of statins in lowering cholesterol levels, do 
people at risk for CHD have equal access to statins?   That is, do disparities in prescribing 
patterns of physicians exist across such factors as the type of insurance the patient has, 
where the patient lives, or the patient’s ethnic/minority status.  Doty and Holmgren 
(2006), based on the Commonwealth Fund Biennial Health Insurance Survey (2005), 
found that uninsured rates for Hispanic and African Americans are one and one-half to 
three times higher than the rate for whites.  A recent report by the Institute of Medicine 
(IOM) (Smedley, Stith, and Nelson, 2002) has documented the inequalities in health care 
received by minorities in the U.S., even in cases where there is similar access to health 
care.  Both the IOM study and the study by the Kaiser Foundation and the American 
College of Cardiology Foundation (2002) found that minorities are less likely than whites 
to receive invasive procedures such as angioplasty, bypass surgery, and thrombolytic 
                                                 
1 Direct costs include hospitals, nursing home, physicians/other professionals, and drugs, and other medical 
durables and home health care.  Indirect costs include lost productivity/morbidity and lost 
productivity/mortality. therapy.  The existence of racial disparities in care is important enough to have resulted in 
a whole issue of Health Affairs (2005) being devoted to the topic.  Results of our study of 
factors associated with physician prescribing patterns for statins will shed light on the 
potential disparities in regards to the access to statins by Black Americans and Hispanics. 
The importance of equity in prescribing practices is magnified when a drug is 
effective in treating a serious medical condition.  Numerous studies have shown that 
statins are more effective than predecessors of similar function in decreasing both LDL 
cholesterol and triglycerides, which are important risk factors for heart disease.  Recent 
studies have also suggested that statins may serve not only as a treatment for reducing 
high LDL cholesterol levels, but also in the prevention of other conditions such as stroke, 
deep vein thrombosis, dementias (including Alzheimer’s disease), and as treatment to 
slow the progression of multiple sclerosis (Noonan, 2003, Manning, 2004).  We were 
unable to find other multivariate studies dealing with prescribing patterns by physicians 
as they relate to statins, so our paper provides initial evidence relating to the equity issues 
regarding access to statins.   
According to Pearson (2007), compliance studies indicate that patients often do 
not follow up on the therapies prescribed by their physicians.  Since our study deals only 
with whether or not the physician prescribes a statin drug, and we do not know whether 
the patient actually filled the prescription, our results provide upper-bound estimates of 
the proportion of the patients who actually end up taking the drugs.  Nonetheless, our 
findings should be of interest to policy makers whose objective is to reduce racial/ethnic 
disparities in cardiac care and health outcomes in general. Section 1 includes a brief discussion of why the particular diagnoses were chosen.  
Section 2 discusses the methodology, including the data source, variables included in the 
analysis, and econometric models underlying the estimations.  Results are shown in 
section 3.  Section 4 includes a summary and conclusions. 
 
1.  Why CHD, Dyslipidemia, and Diabetes?  
 
  Cardiovascular related diseases have been for many years and continue to be the 
leading cause of death for males and females in the United States (American Heart 
Association, 2007).  In 2004, in the U.S., it was estimated that 79.3 million people age 20 
and older had LDL cholesterol levels considered ‘borderline high’ or worse; and high 
LDL cholesterol levels are a risk factor for CHD (Centers for Disease Control, 2006a, 
2006b, American Heart Association, 2007).
2  The incidence of and death rates associated 
with cardiovascular diseases are greater for Blacks compared to whites (American Heart 
Association, 2007).      
  Diabetes affects over 20 million people in the United States and was the sixth 
leading cause of death in the U.S. in 2004.  Type-2 diabetes is the most common type, 
with risk factors including obesity, inactivity, older age, high blood pressure, high 
cholesterol, a family history of diabetes, and ethnicity.  Compared to Caucasians, 
Hispanic/Latino Americans, African Americans, and Asian Americans are twice as likely 
to develop Type-2 diabetes (1 on 1 Health, Centers for Disease Control, 2003, 2005, 
American Heart Association 2007). 
                                                 
2 Levels of 130-159 are borderline high.   Statins have been effective in lowering LDL cholesterol levels.  Use of statins as 
sole means of primary or secondary treatment has been shown to reduce the incidence of 
CHD by 25 to 60 percent and reduce the risk of death from any other heart disease or 
condition by 30 percent (Knopp, 1999).  The use of statins, in addition to providing large 
and significant reductions in deaths due to CHD, does not appear to increase non-CHD or 
cancer related deaths (Hebert et al, 1997).  Reductions in risk for CHD were similar for 
men and women and for elderly and middle-aged patients (LaRosa et al, 1999).  Although 
these results suggest the potential for reducing cholesterol levels in large numbers of 
persons at risk for CHD, other studies have shown that only one-third of eligible patients 
are receiving statins as secondary prevention (Majumdar et al, 1999).  Data from the 
Third Report of the Expert Panel on Detection, Evaluation and Treatment of High Blood 
Cholesterol in Adults (2007) cites results consistent with Majumdar and further notes that 
even among the highest risk patients less than half are getting lipid lowering medications.  
Specific at risk populations in danger of not receiving statins include minorities and 
patients lacking insurance coverage for prescription drugs. 
     One of the most detrimental side effects of diabetes is heart disease and stroke, 
the leading cause of death among diabetics.  For those having diabetes, heart disease 
occurs earlier in life, is two to four times more common than in non-diabetics, and is 
more likely to be fatal.  The use of statins to control cholesterol levels in diabetics is an 
increasingly important method of allowing patients to live with diabetes.
3   
                                                 
3 Studies suggest that all diabetics, including those with high blood pressure, would 
benefit from the use of a statin.  One study included approximately 6,000 diabetic 
patients and only half of these 6,000 showed signs of cardiovascular disease at the time of 
the study.  Interestingly, it found that a daily dose of simvastatin (40 mg) decreased the 
risk of an initial heart attack or stroke by around 30% for diabetes patients and also  
 
2. Data and Methodology 
  The Data 
  The data set utilized in the current study is from the National Ambulatory Medical 
Care Survey (NAMCS) for the years 1992 through 2004 (Schappert S.M. & Nelson C.R. 
(1999); U.S Department of Health and Human Services (2000)).  The NAMCS includes 
data from patient visits to non-federally employed office-based physicians who focus 
mainly on direct patient care.
4  Data for selected patients are entered onto the patient 
record form and include diagnoses, treatments, symptoms, services performed, 
prescriptions given, and various pieces of demographic information.  The physician or 
office staff, and not the patient, enter data into the survey forms.  Specially trained 
interviewers meet with physicians prior to survey participation, and provide them with 
materials and instruction on how to complete the instrument.  Each physician is randomly 




                                                                                                                                                 
reduced the probability of a repeat attack in those who had already suffered one (The 
Doctor's Lounge, 2003).  Other studies of statins and diabetes yielded similar results.  Dr. 
Collins as a result of his study, specifically directed towards diabetics states, “Lowering 
your cholesterol will lower your risk of heart disease, irrespective of what your 
cholesterol level is.  Taking a statin will lower your risk by a third.  And if you continue 
to take it, you will continue to lower your risk.” (DeNoon, 2003)   
 
4 Certain specialties, including anesthesiology, pathology, and radiology are not included in the survey.  
Data was obtained on the National Center for Health Statistics (NCHS) website in the format of self-
extracting files, which contained all survey data as well as descriptions of the survey, record format, codes 
for medications, generic drugs, and various other information files. 
 
5 See http://www.cdc.gov/nchs/about/major/ahcd/namcsdes.htm    Samples 
Three samples we examine include 6,205 patients whose primary diagnosis is 
coronary heart disease, 2,057 with dyslipidemia, and 6,215 diagnosed with diabetes.  The 
primary diagnosis is based on the International Classification of Diseases (ICD-9) coding 
scheme.  Patients with coronary heart disease were those whose primary diagnosis code 
fell between 410.00 and 414.90.  These patients are broadly defined as having ischemic 
heart disease.
6  Patients with dyslipidemia were those whose primary diagnosis code fell 
between 272.00 and 272.90, a group that is broadly defined as having disorders of lipid 
metabolism.
7   The patients who had an ICD-9 code having the first three digits 250 
include a group that is broadly defined as having type-1 or type-2 diabetes.
8                                                      
  A patient’s insurance coverage and source of payment for the office visit was 
indicated by one of several options.  The insurance variables were recoded so that a 
patient fell into one of five insurance categories, reflecting the likelihood that the 
patient’s insurance provided prescription drug coverage.  These groups are: 1) Medicaid, 
2) HMO/Private, 3) Medicare, 4) self-pay, and 5) unknown/blank.  In cases when a 
patient’s record indicated more than one type of insurance, the patient was placed in the 
group among those indicated on his or her record that was most likely to provide 
                                                 
6 More specific sub-groups include acute myocardial infarction (410), other acute and subacute 
forms of ischemic heart disease (411), old myocardial infarction (412), angina pectoris (413), and other 
forms of chronic ischemic heart disease (414).   
 
7 Specific sub-groups within this coding range include hypercholesterolemia (272.0), 
hypertriglyceridemia (272.1), mixed hyperlipidemia (272.2), hyperchylomicronemia (272.3), other 
hyperlipidemia (272.4), lipoprotein deficiencies (272.5), lipodystrophy (272.6), lipidoses, (272.7), other 
disorders of lipid metabolism (272.8), and unspecified disorders of lipid metabolism (272.9). 
 
8 Patients with gestational diabetes were not included in our analysis.   
 prescription drug coverage.  For example, if the record indicated Medicaid and Medicare, 
the patient was placed in the Medicaid group. 
  The Logit Model 
We estimate a multinomial logit model of the probability of a patient being 
prescribed a statin in which independent variables, described more fully below, include  
demographic characteristics, medical condition, and insurance status.  The dependent 
variable has three outcomes:  no treatment, prescribed a statin
9, and prescribed a lipid-
lowering drug other than a statin.
10  
  Demographic explanatory variables utilized in the logit regressions are dummy 
variables for calendar year; patient’s age (<45, 45-64, and 65-74); gender; race/ethnicity 
(Black, Asian, and Hispanic); and residence (Midwest, South, and West; Nonmetro).  
Insurance status is categorized into four categories: Medicaid, Medicare, Selfpay, and 
Unknown.   Classification of secondary diagnoses is based on the patient’s secondary 
diagnosis in the ICD-9 group:  CHD2 (codes 410.00 to 414.90); Hypertension (401.00 
to 405.90); Other Heart Disease (420.00 to 429.90); Vascular Disease (440.00 to 
448.90); Diabetes (250.00 to 250.93); Dyslipidemia (272.00 to 272.90); and All Other 
ICD-9 groups.  For the Diabetes sample only, we also include a variable to measure 
whether a patient’s secondary diagnosis is both dysliplidemia and coronary heart disease.  
                                                 
9 Statins include Atorvastatin or Lipitor, Cerivastatin or Baycol, Fluvastatin or Lescol, 
Lovastatin or Mevacor (Altocor),  Pravastatin or Pravachol, Rosuvastatin or Crestor, 
Simvastatin or Zocor, Simvastatin + Ezetimibe or Vytorin.  Note that Baycol was 
withdrawn from the market in 2001.  The FDA approved Crestor in August 2003 and 
Vytorin in July 2004. 
 
10 The following drugs are included in the other lipid lowering drugs:  Cholestyramine, 
Questran, Lo-Cholest, Prevalite, Colesevelam,WelChol, Colestipol,Colestid, Fenofibrate, 
Tricor, Gemfibrozil, Lopid, Clofibrate, Atromid S, Niacin (nicotinic acid),Ezetimibe, 
Zetia, and Ezetrol. 
   The omitted groups in the logit regressions include the following variables: the 
year 1992, older than age 74, female, white, paid through private insurance (“HMO/Other 
prepaid,” “Private/Commercial Insurance,” “Blue Cross/Blue Shield,” or “Other private 
insurance”), northeast, metro area, and had no co-morbidities (secondary diagnoses). 
  Time dummy variables are included to give us information about the uptake and 
diffusion of statins over the period 1992 through 2004.  We expect their coefficients will 
indicate increased use of statins over time.  Age is a risk factor for CHD and diabetes. 
Clinical guidelines indicate that persons in our three primary condition categories should 
be treated more aggressively for high cholesterol if they exhibit secondary conditions 
(risk factors) such as hypertension, dyslipidemia (for patients with CHD and diabetes), 
and CHD (for patients with diabetes and dyslipemia).  Positive coefficients are expected 
for the variables indicating risk factors for CHD.  The race/ethnicity variables indicate the 
presence or absence of disparities in access to statins along the lines found by the 
Institute of Medicine in regards to cardiac care for minorities.  Although males are more 
likely than females to have CHD, and since statin treatment is effective in both genders, 
we have no a priori prediction for the sign of the coefficient.  The variables indicating the 
method of payment for the office visit will shed light on the importance of the source of 
payment as a potential determinant of whether or not a patient is prescribed a statin drug 
by his or her physician.  We expect that private insurance will be associated with a 
greater likelihood of the patient receiving a statin.  Information about a person’s 
residence--the region of residence in the U.S. and whether he or she lives in a 
metropolitan area--will allow us to determine whether or not where one lives (which is 
not part of clinical guidelines) affects who is prescribed a statin. 3. Results 
In this section we first show the demographic and clinical conditions associated 
with each of the three samples under study.  The logit results are then discussed. 
Sample Means 
Table 1 shows the means for variables associated with the three samples of 
respondents diagnosed with a primary condition of coronary heart disease (CHD, column 
1), dyslipidemia (DYS, column 2), and diabetes (column 3).  Since males are more likely 
to have CHD, the fact that they comprise 63 percent of the sample diagnosed with CHD 
is not surprising.  The percent male drops to around 50 percent for persons diagnosed 
with dyslipidemia or diabetes.  Whites make up more than 83 percent of the CHD and 
DYS samples but only about 70 percent of diabetics.  Blacks comprise between six to 
seven percent percentage of the CHD and DYS samples, while for Hispanics the 
percentages are between 4.7 and 5.8 percent.  These percentages for diabetics jump to 10 
percent for Hispanics and 15.9 percent for Blacks.   The low percentages of Blacks and 
Hispanics in the coronary heart disease and dyslipidemia samples are consistent with 
evidence that minorities comprise a smaller percentage of the samples visiting 
physicians’ offices in ambulatory settings when compared to the percentage they 
comprise of the whole population in the U.S.  This is probably due to Medicaid, where 
the number of solo physicians not accepting new Medicaid patients over the period 1996-
1997 to 2004-2005 has risen from 29 to 35.3 percent.  Similarly for small groups of 
physicians, the percentage declining new Medicaid patients rose from 16.2 percent to 24 
percent over the same period (Cunningham and May, 2006).  Reasons for the increased 
likelihood of physicians’ refusal to take on Medicaid patients include the low payments compared to private insurance along with high administrative costs.  More than half of 
the 52 million Medicaid beneficiaries are from minority groups, more than 20 percent of 
non-elderly African Americans and Latinos (Llanos and Palmer, 2006). 
Method of payment for the physician visit varies by primary diagnosis.  Medicaid 
patients comprise 5 percent of the visits for CHD, 2.5 percent for dyslipidemia, and 9.9 
percent for diabetes.  The percentages for Medicare are 45 percent for CHD, 32 percent 
for diabetics, and 25 percent for those diagnosed with dyslipidemia.  Payment by private 
insurance varies from around 45-48 percent for CHD and diabetes, to 62 percent for 
dyslipidemia.  The age composition of the sample with CHD rises from 3.5 percent for 
those under age 45, to around one-third for each of the three age groups 45-64, 65-74, 
and 75 and older.  The distribution by age differs for patients with dyslipidemia and 
diabetes where the peak of 42 to 47 percent occurs in the 45 – 64 age-group.  
Approximately one third of the patients in each diagnosis category resided in the South, 
while the remainder was evenly divided between the other three regions of the U.S.  The 
vast majority of patients lived in metro areas. 
  Within each diagnosis, the presence of co-morbidities is likely to influence 
physicians’ decisions about whether or not to prescribe lipid-lowering drugs.  Of persons 
diagnosed with CHD, 11 percent also had other heart conditions, 15.1 percent had 
dyslipidemia, 6.5 percent had diabetes, and 13.8 percent had hypertension.  Patients with 
dyslipidemia and diabetes were most likely to have hypertension as the only other 
secondary condition.  About 40 percent of the patients diagnosed with dyslipidemia and 
diabetes had a secondary condition unrelated to the conditions included in table 1.  The percentages of respondents diagnosed with CHD, dyslipidemia, and diabetes, but who 
have no secondary conditions, are 27, 36, and 23 percent respectively.  
Logit results                                                                                                                             
  The results from the logit regressions are shown in table 2 columns 1-2 for CHD, 
columns 3-4 for dyslipidemia, and columns 5-6 for diabetes.  Table 3 shows the resulting 
predicted probabilities.  
   
 
  Time 
  The coefficients for the year dummy variables should be interpreted with respect 
to 1992.  As expected, statin utilization rates increased over time for each diagnosis 
category, and uptake in their usage reflects a substitution for other lipid-altering drugs 
and a decrease in the probability of receiving ‘no treatment.’  Evaluating the logit results 
at the mean values, the probability of receiving a statin in 1992 if the patient had CHD, 
dyslipidemia, or diabetes as the primary condition, was respectively 13.3 percent, 20.9 
percent, and 3.3 percent.  By 2004 these probabilities rose to 50.3 percent, 51.6 percent 
and 28 percent respectively (see Table 3).  The probability of a patient diagnosed with 
CHD not receiving any treatment dropped from 82 to 48 percent.   
  Age  
For persons diagnosed with coronary heart disease, coefficients for all age groups 
are positive and statistically significant at the 10 percent level or higher (2 of 3 significant 
at the 5 percent level), indicating these patients are more likely to receive statins than are 
patients 75 and over.  Although the coefficients are not all statistically significant, a similar pattern is observed for other lipid lowering drugs.  This pattern is likely to reflect 
the controversy surrounding statins and their use on the elderly. While studies have 
shown benefits of reducing LDL cholesterol in reducing the risk of heart attacks and 
stroke, some research suggests that lowering cholesterol in the oldest age group may 
increase the risk of death (MayoClinic.com, 2005). 
Persons with dyslipidemia under the age of 45 were less likely to receive a statin 
than were the oldest patients.  Being in the 65 - 74 age cohort increases the probability of 
being prescribed a statin compared to people in the over 75 age group.  There is no age 
pattern in the prescribing patterns for other lipid lowering drugs.   In the case of diabetics, 
no significant differences by age existed in prescribing patterns for statins.  Diabetics 
aged from 45 through 74 are more likely than the oldest cohorts to be prescribed other 
lipid lowering drugs.  
  Gender  
  Since men are generally at higher risk of developing CHD than women in the 
same age group, we might expect that statins would be more likely to be prescribed to 
men (other factors the same).
11  Although the coefficient is positive, it is only significant 
at the 10 % level, thus providing little support for this conclusion.  For those with 
dyslipidemia and diabetes, gender is not associated with prescribing patterns of statins or 
other lipid lowering medications. 
  Race/ethnicity 
Blacks and Hispanics with CHD are less likely than whites to be prescribed 
statins, with the coefficients of each negative and significant at the 10% level.  Hispanics 
and Asians with dyslipidemia are also less likely than whites to receive a statin, with 
                                                 
11 See http://www.mayoclinic.com/health/coronary-artery-disease/DS00064 coefficients significant at the 5% level.  There are no statistically significant racial 
differences in prescribing patterns for statins for diabetes patients in the time period 
under study.  The only racial/ethnic differences in the ‘other lipid lowering drugs’ 
occurred with Black and Hispanic persons diagnosed with diabetes, where they are less 
likely than whites to be prescribed OLAD drugs. 
Table 3 presents the predicted probabilities of being prescribed a statin drug by 
race/ethnicity group in 2004 for those with CHD, the main diagnosis group where race 
disparities exist.  The probabilities for Blacks, Hispanics, and whites in 2004 are 
respectively 45 percent, 43.3 percent, and 50.9 percent.  For persons with dyslipidemia, 
the corresponding percentages are 53.8, 43.6, and 51.  For diabetics, the figures for 
Blacks, Hispanics, and whites are 25.8%, 31.8%, and 27.6.   
Insurance coverage 
  Inclusion of variables indicating the method of payment for the patient’s visit 
helps in determining the importance of insurance coverage on prescribing patterns of 
physicians.
12  Type of insurance coverage is important in the case of coronary heart 
disease, where the coefficients of Medicare and Medicaid were negative and statistically 
significant at the 5 percent level.  Patients whose main source of payment was Medicaid 
or Medicare were less likely to be prescribed a statin compared to patients with private 
insurance.  None of the other payment variables appear to be important explanatory 
factors in the prescribing process for either statins or non-statin lipid-lowering drugs.  For 
samples including individuals diagnosed with dyslipidemia and diabetes, the insurance 
                                                 
12 Also to note is the likelihood that these insurance data are reflective of more than a price variable.  Since 
socioeconomic data are not available in the NAMCS, method of payment may also be picking up effects of 
factors such as family income and education of the patient.   
 variables were never significant determinants of whether or not a patient received a statin 
other than for unknown insurance where the patient was less likely than a privately 
insurance patient to receive a statin. As shown in table 3, the probability of a CHD patient 
being prescribed a statin in 2004 varies from 54.8 percent for those having private 
insurance to 47.6 percent for those in the Medicare category and 38.3 percent for those 
with Medicaid. 
 
  Secondary conditions  
  The presence of co-morbidities is stressed in clinical guidelines as an important 
factor affecting decisions to prescribe lipid lowering drugs.  The presence of a secondary 
condition has a positive and statistically significant impact on the probability of being 
prescribed a statin in 19 out of 32 combinations.  Although the remaining coefficients are 
not statistically significant, they are with three exceptions positive.
 13   
  Table 3 shows the probabilities associated with the presence or absence of 
secondary conditions for the samples with coronary heart disease, dyslipidemia, and 
diabetes respectively.  The probabilities of being prescribed a statin in 2004 are 
calculated with all variables held at their means except for time (= 2004) and the 
secondary condition indicated.  The probability standing out for CHD patients occurs 
when dyslipidemia is also present.  In this case the probability rises to 75.4% (compared 
to the mean for 2004 of 50.3%).  Patients with dyslipidemia who have a secondary 
condition of CHD, hypertension, or diabetes each have a probability of about 62% of 
being prescribed a statin (compared to the probability at the means of 51.6%).  Diabetics 
at the mean values of the variables in 2004 have a probability of 28% of being prescribed 
                                                 
13 The only negative coefficients never approached statistical significance.   a statin.  When the person had a secondary condition of CHD, dyslipidemia, or 
dyslipidemia and CHD combined, the probabilities jumped to 44.9%, 57.9%, and 80.1% 
respectively.  All of these results support the clinical guidelines that persons with primary 
conditions of CHD, dyslipidemia, and diabetes should be treated more aggressively than 
those not having secondary conditions.   Patients diagnosed with a primary condition of 
CHD, dyslipidemia, or diabetes but no secondary condition, have a significantly lower 
probability of receiving a statin drug, 44%, 45.8%, and 19.4% respectively. 
  Geographic variation  
The logit models reveal geographic disparities in prescribing patterns in the case 
of CHD and dyslipidemia. The probability of being prescribed a statin tends to be lower 
in all regions compared to the Northeast.  CHD Patients residing in the Midwest and 
South are also less likely to be prescribed other lipid lowering drugs than similarly 
situated patients in the Northeast.  Obviously, no clinical guidelines suggest that a patient 
living in one region of the country should be more likely to receive statins.  These 
disparities add further support to the already documented differences in prescribing 
patterns across the United States (Burton, 2001); such disparities no longer come as a 
surprise, although they continue to foster concerns.   
4. Summary and Conclusions 
  Coronary heart disease is the leading cause of death in the United States and high 
levels of LDL cholesterol, along with diabetes, are risk factors for cardiovascular disease. 
This, along with the fact that statin therapy lowers LDL cholesterol and is beneficial to 
patients at risk for heart disease, including diabetics, led us to examine the prescribing 
patterns of physicians for samples of patients who have primary diagnoses of coronary heart disease, dyslipidemia, and diabetes.  Obviously, the benefits from statins can be 
realized only if physicians are prescribing them to patients at risk of CHD.     
  Our results provide further evidence of racial/ethnic disparities, in this instance 
with respect for prescription drugs, since Blacks and Hispanics diagnosed with the 
primary condition of coronary heart disease (CHD) are less likely to be prescribed a 
statin.  The predicted probabilities in 2004 for Blacks, Hispanics and whites are 
respectively 45%, 43.3%, and 51% respectively.  This result is troubling but consistent 
with the results of the recent study conducted by the Institute of Medicine (IOM), which 
found that in many aspects of health care, including cardiac, minorities receive lower 
quality care compared to whites.  The IOM study found persistent racial/ethnic 
differences in care even after controlling for such factors as access to the system, 
insurance status, and socioeconomic status.   
  Another major result is that CHD patients covered by Medicare or Medicaid were 
less likely to have been prescribed a statin compared to their counterparts who have 
private insurance.  Medicaid (Medicare) patients were 16.5 (7.2) percentage points less 
likely to receive a statin compared to similarly situated persons having private health 
insurance.   
  Patients having a risk factor along with their primary diagnosis were more likely 
to receive a statin than those without a secondary condition.  For example, the probability 
is 75.4% for coronary heart patients who also have dyslipidemia.  Diabetics exhibiting 
co-morbidities of coronary heart disease or a combination of both coronary heart disease 
and dyslipidemia have probabilities of 44.9 and 80.1 percent, respectively.   While the probability of being prescribed a statin has increased significantly over 
time for persons of all races and insurance types, the disparity in probabilities across 
races and insurance types has widened considerably.  If this trend continues, non-white 
and publicly insured persons will trail by an ever greater margin white and privately 
insured persons for access to statins.  Because of the racial issues associated with health 
insurance as well as access to care, equity in regards to prescription drugs must be a 
major issue in discussions of health care reform in the U.S.  
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Disease  Dyslipidemia  Diabetes 
Medicaid  0.050  0.025  0.099 
Private Insurance  0.447  0.618  0.484 
Unknown  0.030  0.040  0.042 
Medicare  0.445  0.247  0.318 
Self insured  0.023  0.057  0.050 
Male  0.631  0.500  0.473 
Hispanic  0.047  0.058  0.100 
White  0.864  0.835  0.702 
Black  0.062  0.070  0.159 
Northeast  0.267  0.212  0.202 
Midwest  0.211  0.237  0.238 
South  0.304  0.336  0.340 
West  0.218  0.215  0.220 
Non-metro area  0.141  0.196  0.219 
Age under 45  0.035  0.181  0.142 
Age 45-64  0.315  0.472  0.418 
Age 65- 74  0.326  0.239  0.267 
Age 75+  0.324  0.108  0.173 
Statin prescribed  0.331  0.427  0.160 
Other Lipid Altering     
Drug  0.046  0.094  0.025 
No lipid lowering drug  0.642  0.510  0.821 
Other Heart Disease  0.111  0.020  0.020 
Dyslipidemia  0.151    0.091 
Diabetes  0.065  0.029   
Hypertension  0.138  0.153  0.200 
Coronary Heart 
Disease    0.053  0.044 
Vascular  0.018  0.002  0.011 
No other conditions  0.274  0.360  0.228 
Dyslipidemia/Coronary 
Heart Disease      0.005 
Other conditions  0.240  0.382  0.401 
Number of 
observations  6,205  2,057  6,215 Table 2: Multinomial Logit Estimates for the Probability that a Statin is Prescribed by a 




Disease  Dyslipidemia  Diabetes 












Constant  -2.038** -3.355** -0.996**  -1.343**  -3.953**  -5.218** 
   (0.175)  (0.363)  (0.314)  (0.474)  (0.313)  (0.613) 
1993  -0.622**  -0.507  0.242  -0.828**  0.065)  -0.721 
   (0.232)  (0.344)  (0.308)  (0.376)  (0.370)  (0.551) 
1994  0.006  -0.305  0.463  -0.911**  0.125  -0.207 
   (0.191)  (0.311)  (0.303)  (0.391)  (0.352)  (0.475) 
1995  0.257  -0.097  0.288  -0.879**  0.491  0.056 
   (0.181)  (0.292)  (0.302)  (0.368)  (0.324)  (0.440) 
1996  0.664**  -0.349  0.370  -1.322**  0.834**  0.031 
   (0.181)  (0.341)  (0.309)  (0.431)  (0.317)  (0.475) 
1997  1.162**  -0.845**  1.060**  -1.634**  1.312**  0.020 
   (0.170)  (0.380)  (0.292)  (0.521)  (0.307)  (0.482) 
1998  1.370**  -1.232**  0.724**  -1.365**  1.295**  -0.255 
   (0.173)  (0.469)  (0.308)  (0.492)  (0.304)  (0.491) 
1999  1.809**  -0.935*  1.109**  -2.110**  1.747**  -0.779 
   (0.187)  (0.555)  (0.296)  (0.641)  (0.297)  (0.586) 
2000  1.631**  -1.005**  1.103**  -1.288**  1.918**  -0.696 
   (0.171)  (0.443)  (0.295)  (0.467)  (0.291)  (0.535) 
2001  1.854**  -0.579  0.916**  -2.063**  1.979**  -0.910* 
   (0.176)  (0.413)  (0.293)  (0.568)  (0.291)  (0.558) 
2002  1.673**  -0.863**  1.245**  -1.242**  2.283**  -0.639 
   (0.172)  (0.426)  (0.279)  (0.415)  (0.284)  (0.488) 
2003  2.143**  -0.417  1.157**  -1.195**  2.600**  -0.444 
   (0.181)  (0.449)  (0.284)  (0.427)  (0.287)  (0.533) 
2004  1.865**  -0.600  1.183**  -1.353**  2.428**  -0.026 
   (0.177)  (0.429)  (0.284)  (0.445)  (0.288)  (0.478) 
Age under 45  0.300*  0.816**  -0.585**  0.055  -0.019  0.524 
   (0.181)  (0.416)  (0.218)  (0.402)  (0.162)  (0.478) 
Age 45-64  0.278**  0.709**  0.195  -0.010  0.024  1.016** 
   (0.090)  (0.243)  (0.189)  (0.365)  (0.125)  (0.393) 
Age 65-74  0.363**  0.202  0.318*  0.017  0.014  0.858** 
   (0.076)  (0.232)  (0.176)  (0.337)  (0.115)  (0.386) 
Male  0.106*  0.238  0.049  -0.034  -0.021  0.292 
   (0.064)  (0.180)  (0.100)  (0.200)  (0.078)  (0.194) Table 2 Continued. 
  
Coronary Heart 
Disease  Dyslipidemia  Diabetes 













Black  -0.254**  -0.421  0.032  -0.280  -0.109  -1.496** 
   (0.130)  (0.433)  (0.192)  (0.452)  (0.114)  (0.472) 
Asian  -0.035  0.500  -0.478*  0.250  0.211  -0.098 
   (0.192)  (0.409)  (0.288)  (0.438)  (0.200)  (0.467) 
Hispanic  -0.313**  -0.088  -0.342*  0.171  0.189  -0.653* 
   (0.149)  (0.406)  (0.213)  (0.407)  (0.132)  (0.366) 
Medicaid  -0.685**  -0.756  0.142  0.382  0.053  0.490 
   (0.164)  (0.476)  (0.327)  (0.530)  (0.146)  (0.318) 
Unknown  
Insurance  -0.525**  -0.067  -0.560**  -0.481  -0.120  0.077 
   (0.182)  (0.445)  (0.258)  (0.546)  (0.196)  (0.492) 
Medicare  
Insurance  -0.289**  -0.051  0.002  0.183  0.145  -0.266 
   (0.077)  (0.212)  (0.149)  (0.294)  (0.107)  (0.282) 
Self Pay  -0.202  0.000  0.007  0.511  -0.080  -0.447 
   (0.219)    (0.225)  (0.346)  (0.209)  (0.493) 
Midwest  -0.163*  -0.593**  -0.256*  0.403  0.190  0.156 
   (0.089)  (0.247)  (0.145)  (0.282)  (0.118)  (0.288) 
South  -0.103  -0.557** -0.454**  -0.310  0.095  0.069 
   (0.081)  (0.220)  (0.134)  (0.293)  (0.111)  (0.278) 
West  -0.151*  -0.117  -0.475**  0.051  -0.140  0.279 
   (0.090)  (0.215)  (0.151)  (0.304)  (0.128)  (0.298) 
Non-metropolitan 
 area  -0.124  -0.265  0.003  0.305  0.047  -0.306 
   (0.091)  (0.256)  (0.125)  (0.231)  (0.095)  (0.253) 
Dyslipidemia  1.487**  2.085**      1.946**  3.243** 
   (0.096)  (0.228)      (0.136)  (0.334) 
Coronary Heart 
Disease      0.773**  0.810*  1.261**  1.726** 
       (0.230)  (0.419)  (0.182)  (0.446) 
Dyslipidemia/ 
Coronary Heart 
Disease          3.032**  3.305** 
           (0.471)  (0.876) 
Hypertension  0.164*  0.183  0.675**  0.370  0.953**  0.958** 
   (0.098)  (0.317)  (0.149)  (0.306)  (0.123)  (0.369) Other Heart 
 Disease  0.019  0.286  -0.032  0.514  0.816**  1.642** 
   (0.108)  (0.327)  (0.351)  (0.584)  (0.270)  (0.599) 
Other 
Table 2 Continued. 
 
 conditions  0.058  0.297  0.201*  0.073  0.075  -0.171 
   (0.084)  (0.245)  (0.114)  (0.228)  (0.118)  (0.381) 
Diabetes  -0.012  0.239  0.789**  1.058*     
   (0.132)  (0.383)  (0.303)  (0.544)     
** = Significant at the 5% level. 
* = Significant at the 10% level.  No coronary heart disease sufferers who are prescribed 
an other lipid altering drug reported self pay insurance, resulting in a fixed parameter for 
the combination of chd/olad/self pay. 
 
   
Table 3:  Predicted Probabilities Associated with a Patient Being Prescribed a Statin in 
2004, by Selected Characteristics.* 
  Coronary heart disease   Dyslipidemia  Diabetes 
Characteristics    Statin 
Other lipid 
lowering 
drug  Statin 
Other lipid 
lowering 




At Means, 1992  0.133  0.047  0.209  0.204  0.033  0.014 
At Means, 2004  0.503  0.015  0.516  0.040  0.280  0.011 
Black  0.450  0.011  0.538  0.029  0.258  0.004 
White  0.510  0.015  0.525  0.039  0.276  0.015 
Hispanic  0.433  0.016  0.436  0.054  0.318  0.008 
Private  0.548  0.015  0.521  0.037  0.271  0.012 
Medicaid  0.383  0.010  0.548  0.050  0.279  0.019 
Medicare  0.476  0.016  0.518  0.044  0.301  0.009 
Dyslipidemia  0.754  0.034      0.579  0.081 
Other heart disease  0.444  0.014  0.439  0.063  0.344  0.030 
Hypertension  0.480  0.012  0.617  0.038  0.381  0.015 
Diabetes  0.436  0.014  0.623  0.068     
Coronary Heart 
Disease      0.628  0.054  0.449  0.027 
Coronary Heart 
Disease/Dyslipidemi
a          0.801  0.040 
No comorbidities  0.440  0.011  0.458  0.038  0.194  0.007 
 
*The first (second) row is calculated at the means for all variables in 1992 (2004).  All 
other rows are for 2004, and assume that all variables but the one indicated in the row of 
interest are at their mean values for 2004. 
 
 
 
 
 
 
 
 
 
 
 
 